SINOMAB BIO-B (03681) releases interim results, with research and development costs of 32.74 million yuan. Both core drug pipelines have achieved breakthrough progress.

SINOMAB BIO-B (03681) released its mid-term financial results for 2025, with other revenue and income totaling 98.02 million yuan, a year-on-year increase of 126.95%; research and development costs amounted to 32.74 million yuan. The announcement stated that during the reporting period, the company's two core drug pipelines, Suciraslimab (SM03) and SM17, both made breakthrough progress. The group's flagship product, Suciraslimab, is the world's first monoclonal antibody (mAb) targeting the CD22 target. Recently, Suciraslimab achieved breakthrough results in preclinical studies for the treatment of systemic lupus erythematosus (SLE). With its unique advantage of "regulating the autoimmune network through B cell interaction + organ damage protection benefits", Suciraslimab not only significantly reduces levels of anti-double-stranded DNA (anti-dsDNA) antibodies, but also demonstrates advantages over existing drugs in improving lupus nephritis (LN) proteinuria and kidney pathological damage. In the first half of 2025, the total amount of China's innovative drug licensing-out transactions reached 66 billion US dollars, a year-on-year increase of 36%, an increase of about 27.2% over the total of 51.9 billion US dollars in 2024. Among the licensed projects, over 50% involve preclinical or Phase 1 clinical trials, reflecting international pharmaceutical companies' recognition of early Chinese innovation. In addition, the National Medical Products Administration has compressed the approval time for innovative drug clinical trials from 14 months to 30 days, and the National Healthcare Security Administration's "Sixteen Measures on Innovative Drugs" support payment expansion has also promoted the recovery of the Chinese innovative drug market. The central "new productive forces" strategy also provides a favorable environment for the group's innovative research and development. As the first 18A biopharmaceutical company based in Hong Kong, the group will continue to focus on innovation as its core competitive advantage, promoting the commercialization of existing drug pipelines and the research and development of new drug pipelines. The group also believes that Suciraslimab and SM17 will further validate their best-in-class characteristics in subsequent clinical trials, addressing unmet medical needs for SLE and AD patients.